[ESMO ASIA 2022(싱가포르) = 황재선 기자] ESMO ASIA CONGRESS 2022 (European Society of Oncology Asian Annual Conference), a festival of global researchers and bio pharmaceutical companies researching new anti-cancer drugs, kicked off on the 2nd at the Suntec City Convention and EXHIBITION Center in Singapore.
The official schedule for this event runs from the 2nd to the 5th. Additional publication schedules will be held from the 6th onwards, and research results on different types of cancer such as lung cancer, liver cancer, breast cancer, bladder cancer, and endometrial cancer will also be presented.
In addition, each sponsoring company will set up a booth to present its pipeline. This event was sponsored by major global pharmas such as Amgen, Astellas, AstraZeneca, Bayer, Beigene, Daiichi Sankyo, GSK, Merck, MSD, Novartis, and Pfizer.
Researchers representing all academic communities were invited to the opening ceremony, including Chair of ESMO, Solange Peters and Dr. Janil Puthucheary from Singapore’s Ministry of Health.
Chairman Solange said, “Currently, 28,000 members are active in 160 countries, and 24% are in the Asia-Pacific region.” I want it to be a place to do that,” he said.
Meanwhile, among domestic companies, Yuhan Corporation plans to participate in the event and present the first-line treatment effect phase 3 clinical results (LASER301 study) for Lexraza (ingredient: Lazertinib) in non-small cell lung cancer patients with EGFR mutation. The speaker was Professor Cho Byeong-cheol (Yonsei Cancer Hospital).
In addition, AstraZeneca presents the clinical results of Imfinzi (ingredient name: durvalumab) and Tagrisso (ingredient name: osimertinib), and MSD presents ‘KN045′ for the bladder cancer indication of Keytruda (ingredient name: pembrolizumab).’, ‘KN052’ research Asian data will be presented.
